Abstract
By treating acute leukemia and lymphoma in the conventional way, a physician can inadvertently deny patients the full benefit of potentially curative therapy. During the last 10 years, intensive combination therapy with agents belonging to five new classes has produced long-term remissions. However, patients who have been treated conventionally do not respond as well as previously untreated patients and may become resistant to one or more of these agents.